Hubei Biocause Heilen Pharmaceutical (301211.SZ) has received a drug registration certificate.

Hubei Biocause Heilen Pharmaceutical (301211.SZ) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Torasemide Injection. Torasemide is a highly efficient and long-acting loop diuretic, suitable for the long-term management of heart failure, liver cirrhosis, and renal edema. Its oral bioavailability is high and the risk of hypokalemia is relatively low. Torasemide Injection is classified as a Class 3 chemical drug registration, and it has been evaluated and approved based on the technical requirements consistent with the quality and efficacy of the reference product. Approval is considered equivalent to passing the evaluation of consistency in quality and efficacy of generic drugs.